Notice of Pre-AIA or AIA Status
The present application is being examined under the pre-AIA first to invent provisions.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-5, 16-20, 44-47 and 65-69 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 9-17 and 23-34 of U.S. Patent No. 8,911,786. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a method of treating cancer in an individual comprising administration to the individual an effective amount of a composition comprising nanoparticle rapamycin. The cancers both include renal cell carcinoma and the formulations both comprise human serum albumin. The nanoparticles are no larger than 200 nm and the method further comprises an additional agent and treatment components such as chemotherapy. The scope, however, are not reference claims recite an effective range for the rapamycin nanoparticle and the instant claims are broader and do not recite a range. It would have been obvious to determine the optimal workable ranges for the rapamycin composition to arrive at the claimed ranges through routine experimentation by those of ordinary skill in the art. The scopes overlap and would act as art over one another and as such cannot be allowed together.
Claims 1, 2, 16, 18, 20, 44-47 and 65-69 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3 and 4 of U.S. Patent No. 9,399,072. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a method of treating cancer by administering a nanoparticulate rapamycin composition that comprises a carrier protein. The formulation further comprises an additional chemotherapeutic agent administered with the rapamycin nanoparticles. The claims overlap in scope in the types of cancers treated, however the reference claims further recite that the individual receiving the treatment was stopped for 6 months. The overlapping scopes overlap and would act as art over one another and as such cannot be allowed together.
Claims 1, 2, 16, 18, 20, 44-47 and 65-69 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 4, 7, 8, 12 and 19 of U.S. Patent No. 9,399,071. Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a method of treating cancer by administering a nanoparticulate rapamycin composition that comprises a carrier protein. The formulation further comprises an additional chemotherapeutic agent administered with the rapamycin nanoparticles. The claims overlap in scope in the types of cancers treated, however the reference claims further recite that the individual receiving the treatment was stopped for 6 months. The overlapping scopes overlap and would act as art over one another and as such cannot be allowed together.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
Claim(s) 1-5, 16-20, 44 and 45 is/are rejected under pre-AIA 35 U.S.C. 102b as being anticipated by Desai et al (US 2005/0004002 A1 hereafter Desai).
Desai teaches a method of treating cancers comprising the administration of a pharmaceutical composition comprising a pharmaceutical agent attached to a carrier protein. The carrier protein is human serum albumin, and the pharmaceutical agent is rapamycin [abstract, claims]. The rapamycin when included in the formulation is present in the form of nanoparticles under the 200 nm [0031]. The weight ratio of carrier protein to rapamycin is no more 18:1 [0014]. The formulation is useful in treating humans with lung cancer and other soft tissue tumors (plasmacytomas) [0031, 0046, and 0048]. The method of treating includes additional chemotherapy agents [0047]. These disclosures render the claims anticipated.
Claim Rejections - 35 USC § 103
The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claim 1-3, 5, 16-20, 44-47 and 65-69 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Desai et al (US 2005/00004002 A1 hereafter Desai) in view of Iverson et al (US 2004/0126400 A1 hereafter Iverson).
As discussed above the Desai discloses a method of treating various cancers in an individual comprising administering to the individual an effective amount of rapamycin. The combination is however silent to the inclusion of specific chemotherapy agents of claims 47. The use of these agents is well known in the art as seen in the Iverson patent.
Iverson discloses a nanoparticle formulation comprising rapamycin that is applied to treat tumors [abstract, 0029]. The formulation is delivered to a human patient in need thereof [0032]. The formulation comprises a carrier protein such as human serum albumin [0028, 0036, claim 3]. The nanoparticles range in size from 50-750 nm [0045]. The formulation further comprises other chemotherapy agents including kinase inhibitors, tamoxifen, 5-fluorouracil and cyclophosphamide [0030, 0048]. The formulation can be used to treat a variety of cancers including bladder cancer [0051]. It would have been obvious to combine the prior art in order to directly treat tumor sites.
With these aspects in mind, it would have been obvious to combine the prior art in order to directly treat tumors in various locations including the bladder. It would have been obvious to treat a variety of cancers in a single formulation. This combination would have been obvious since each publication and patent discloses the use of rapamycin to treat tumors. One of ordinary skill in the art would have been motivated to combine the prior art with an expected result of a stable cancer fighting formulation.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICAH PAUL YOUNG whose telephone number is (571)272-0608. The examiner can normally be reached Monday through Friday, 9:00 am to 5:30 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on 5712720616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MICAH PAUL YOUNG/Primary Examiner, Art Unit 1618